



# Lyka Labs Limited



## MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,  
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry@lykalabs.com

### STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2012

Particular	Rs. In Lacs				
	3 Months Ended	Preceding 3 Months Ended	Corresponding 3 Months Ended	Year to date figure for current period Ended	Previous Accounting year ended
	31-Mar-2012 (Unaudited)	31-Dec-2011 (Unaudited)	31/03/2011 in the previous year (Unaudited)	31/03/2012 (18 Months) (Unaudited)	30/09/2010 (12 Months) (Audited)
<b>1 Income from operations</b>					
(a) Net Sales/Income from operations (Net of excise duty)	2191.16	1713.60	2061.17	13434.40	11582.01
(b) Other Operating Income	79.15	113.92	110.03	561.89	287.92
<b>Total income from operations (net)</b>	<b>2,270.31</b>	<b>1827.51</b>	<b>2171.20</b>	<b>13,996.30</b>	<b>11869.93</b>
<b>2 Expenses</b>					
(a) Cost of Materials Consumed	1299.20	881.20	1232.58	6,745.15	5215.50
(b) Purchase of traded goods	293.00	150.16	171.96	2660.66	2820.13
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	-116.37	106.88	2.71	-148.81	-188.56
(d) Employee benefits expense	275.61	252.89	292.20	1689.64	1030.84
(e) Depreciation and amortisation expense	91.37	90.23	115.71	541.15	339.59
(f) Other expenses	401.53	318.31	344.03	2190.01	1447.51
<b>Total expenses</b>	<b>2244.35</b>	<b>1799.67</b>	<b>2159.19</b>	<b>13677.80</b>	<b>10665.01</b>
<b>3 Profit/(Loss) from Operations before Other Income, Finance cost and Exceptional items (1-2)</b>	<b>25.96</b>	<b>27.85</b>	<b>12.01</b>	<b>318.49</b>	<b>1204.92</b>
<b>4 Other Income</b>	<b>178.24</b>	<b>62.44</b>	<b>52.42</b>	<b>478.89</b>	<b>220.18</b>
<b>5 Profit/(Loss) from ordinary activities before finance cost and exceptional Items (3+4)</b>	<b>204.21</b>	<b>90.29</b>	<b>64.44</b>	<b>797.38</b>	<b>1425.10</b>
<b>6 Finance costs</b>	<b>357.29</b>	<b>448.98</b>	<b>337.48</b>	<b>2244.55</b>	<b>1112.12</b>
<b>7 Profit/(Loss) from ordinary activities after finance cost but before exceptional Items (5+6)</b>	<b>-153.09</b>	<b>-358.69</b>	<b>-273.04</b>	<b>-1447.16</b>	<b>312.98</b>
<b>8 Exceptional Items (Net)</b>	<b>746.91</b>	<b>272.58</b>	<b>-138.24</b>	<b>881.25</b>	<b>-138.24</b>
<b>9 Profit/(Loss) from Ordinary Activities before tax (7+8)</b>	<b>593.83</b>	<b>-86.10</b>	<b>-411.28</b>	<b>-565.92</b>	<b>174.74</b>
<b>10 Tax Expenses</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>-6.26</b>
<b>11 Net Profit/(Loss) from Ordinary activities after tax (9+10)</b>	<b>593.83</b>	<b>-86.10</b>	<b>-411.28</b>	<b>-565.92</b>	<b>181.00</b>
<b>12 Extraordinary Item (net of tax expenses)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>13 Net Profit/(Loss) for the period (11+12)</b>	<b>593.83</b>	<b>-86.10</b>	<b>-411.28</b>	<b>-565.92</b>	<b>181.00</b>
<b>14 Paid up equity share capital (face value Rs.10/- per share)</b>	<b>2158.00</b>	<b>2158.00</b>	<b>2158.00</b>	<b>2158.00</b>	<b>2158.00</b>
<b>15 Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>5217.18</b>
<b>16 i. Earnings Per Share (before extraordinary items) (of Rs 10/-each (not annualised))</b>					
(a) Basic	2.75	-0.40	-1.91	-2.62	0.84
(b) Diluted	2.75	-0.40	-1.91	-2.62	0.84
<b>16 ii. Earnings Per Share (After extraordinary items) (of Rs 10/-each (not annualised))</b>					
(a) Basic	2.75	-0.40	-1.91	-2.62	0.84
(b) Diluted	2.75	-0.40	-1.91	-2.62	0.84



# Lyka Labs Limited



## MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,  
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry@lykalabs.com

### STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2012

Particular	3 Months Ended	Preceding 3 Months Ended	Corresponding 3 Months Ended	Year to date figure for current period Ended	Rs. In Lacs
					Previous Accounting year ended
	31-Mar-2012	31-Dec-2011	31/03/2011 in the previous year	31/03/2012 (18 Months)	30/09/2010 (12 Months)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>A PARTICULARS OF SHAREHOLDING</b>					
1 Public Shareholding					
Number of shares	16552735	16552735	16552735	16552735	16552735
percentage of shareholding	76.70	76.70	76.70	76.70	76.70
2 Promotors and promoter group - Shareholding					
a. Pledged / Encumbered					
- Numbers of Shares	4965615	4981515	4546615	4965615	4133415
- Percentage of shares (as a % of the total shareholding of promotor and promotor group)	98.77	99.09	90.44	98.77	82.22
- Percentage of shares (as a % of the total share capital of the company)	23.01	23.08	21.07	23.01	19.15
b. Non - encumbered					
- Number of shares	61650	45750	480650	61650	893850
- Percentage of shares (as a % of the total shareholding of promotor and promotor group)	1.23	0.91	9.56	1.23	17.78
- Percentage of shares (as a % of the total share capital of the company)	0.29	0.22	2.23	0.29	4.15

PARTICULARS		3 Month ended
Pending at the beginning of the quarter		-
Received during the quarter		2
Disposed of during the quarter		2
Remaining unresolved at the end of the quarter		-



Notes:

1. The above results were duly considered by the Audit Committee on 15<sup>th</sup> May 2012, and taken on record by the Board of Directors of the Company along with Limited Review Report carried out by the Auditors at its meeting held on 15<sup>th</sup> May, 2012.
2. During the Quarter the Company has charged Rs. 24.73 lacs being depreciation on revalued assets.
3. The Company has capitalised a sum of Rs. 15.01 lacs being Interest towards the Term Loan for Tarapur Upgradation, during the quarter.
4. Exceptional items includes Profit of Rs. 759.39 lacs on sale of Fixed Assets during the quarter.
5. The Company's factory at Tarapur is under upgradation. In view of this the production has been suspended.
6. Accounting year of the Company has been extended by six months i.e. from 30<sup>th</sup> September, 2011 to 31<sup>st</sup> March, 2012 covering a period of 18 months which has been approved by the Registrar of Companies, Gujarat, vide their letter dated 30/09/2011.
7. The Company has one Single Segment "Pharmaceuticals".
8. Previous periods figures have been regrouped/rearranged wherever necessary.
9. Audit qualifications in respect of Audited Accounts for 2009-10 and management comments thereon are detailed below:

Regarding the Revaluation of its Fixed Assets again and writing off/adjustment of stocks, overdue debtors, loans & advances and deferred revenue expenditure, the management is of the view that such extra-ordinary items relating to the past years could legitimately be written off against the 'net present replacement value'

For L YKA LABS LIMITED

  
(N. I. GANDHI)

Chairman & Managing Director

Mumbai  
15-May-12.



# Lyka Labs Limited



## MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,  
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry@lykalabs.com

### STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2012 (Rs. in Lacs)

	3 Months Ended 31/03/2012	Preceding 3 Months Ended 31/12/2011	Corresponding 3 Months Ended 31/03/2011 in the previous year	Year To Date Figures For Current period ended 31/03/2012 (18 months)	Previous Accounting Year ended 30/09/2010 (12 months)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1 Income from operations</b>					
(a) Net Sales/Income from operations (Net of excise duty)	2,762.47	2,018.12	2,765.83	16200.96	13912.32
(b) Other Operating Income	134.62	70.80	167.14	706.95	820.15
<b>Total income from operations (net)</b>	<b>2,897.10</b>	<b>2,088.92</b>	<b>2,932.97</b>	<b>16,907.92</b>	<b>14,732.47</b>
<b>2 Expenses</b>					
(a) Cost of Materials Consumed	1,299.20	881.20	1,232.58	6745.15	5215.50
(b) Purchase of traded goods	456.05	244.01	375.30	3644.34	3511.22
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	-130.75	119.45	2.71	-171.58	-183.12
(d) Employee benefits expense	341.19	284.37	335.72	1924.82	1176.90
(e) Depreciation and amortisation expense	144.74	143.21	168.63	860.05	568.56
(f) Other expenses	637.66	500.66	585.45	3395.18	2469.28
<b>Total expenses</b>	<b>2,748.08</b>	<b>2,172.90</b>	<b>2,700.39</b>	<b>16397.96</b>	<b>12758.35</b>
<b>3 Profit/(Loss) from Operations before Other Income, Finance cost and Exceptional items (1-2)</b>	<b>149.02</b>	<b>-83.98</b>	<b>232.58</b>	<b>509.95</b>	<b>1974.12</b>
4 Other Income	123.59	81.64	50.72	412.90	150.56
<b>5 Profit/(Loss) from ordinary activities before finance cost and exceptional items (3+4)</b>	<b>272.61</b>	<b>-2.34</b>	<b>283.30</b>	<b>922.85</b>	<b>2124.68</b>
6 Finance costs	550.47	576.85	535.05	3026.03	1719.57
<b>7 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5+6)</b>	<b>-277.86</b>	<b>-579.19</b>	<b>-251.75</b>	<b>-2103.17</b>	<b>405.11</b>
8 (i) Exceptional Items (Net)	1,159.11	272.58	-158.64	1273.06	-138.24
(ii) Provision for Taxation of earlier years	0.00	0.00	-	0.00	6.26
<b>9 Profit/(Loss) from Ordinary Activities before tax (7+8)</b>	<b>881.26</b>	<b>-306.61</b>	<b>-410.39</b>	<b>-830.13</b>	<b>273.13</b>
10 Tax Expenses	0.00	0.00	-	0.00	0.00
<b>11 Net Profit/(Loss) from Ordinary activities after tax (9+10)</b>	<b>881.26</b>	<b>-306.61</b>	<b>-410.39</b>	<b>-830.13</b>	<b>273.13</b>
12 Extraordinary Item (net of tax expenses)	0.00	0.00	-	0.00	0.00
<b>13 Net Profit/(Loss) for the period (11+12)</b>	<b>881.26</b>	<b>-306.61</b>	<b>-410.39</b>	<b>-830.13</b>	<b>273.13</b>
14 Share of Profit/(Loss) of associates	0.00	0.00	0.00	0.00	0.00



# Lyka Labs Limited



## MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,  
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry@lykalabs.com

### STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2012 (Rs. in Lacs)

	3 Months Ended 31/03/2012	Preceding 3 Months Ended 31/12/2011	Corresponding 3 Months Ended 31/03/2011 in the previous year	Year To Date Figures For Current period ended 31/03/2012 (18 months)	Previous Accounting Year ended 30/09/2010 (12 months)	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
15	Minority interest	0.00	0.00	0.00	0.00	
16	Net Profit/ (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	881.26	-306.61	-410.39	-830.13	273.13
17	Paid up equity share capital ( face value Rs.10/- per share)	2158.00	2158.00	2158.00	2158.00	2158.00
18	Reserve excluding Revaluation Reserve as per Balance Sheet of previous accounting year	0.00	0.00	-	0.00	7965.54
19 i.	<b>Earnings Per Share (before extraordinary items) (of Rs 10/-each (not annualised))</b>					
	(a) Basic	4.08	-1.42	-1.90	-3.85	1.27
	(b) Diluted	4.08	-1.42	-1.90	-3.85	1.27
19 ii.	<b>Earnings Per Share (After extraordinary items) (of Rs 10/-each (not annualised))</b>					
	(a) Basic	4.08	-1.42	-1.90	-3.85	1.27
	(b) Diluted	4.08	-1.42	-1.90	-3.85	1.27
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>					
1	Public Shareholding					
	- Number of shares	16552735	16552735	16552735	16552735	16552735
	- Percentage of shareholding	76.70	76.70	76.70	76.70	76.70
2	Promoters and promoter group - Shareholding					
a.	Pledged / Encumbered					
	- Numbers of Shares	4965615	4981515	4546615	4965615	4133415
	- Percentage of shares (as a % of the total shareholding of promotor and promotor group)	98.77	99.09	90.44	98.77	82.22
	- Percentage of shares (as a % of the total share capital of the company)	23.01	23.08	21.07	23.01	19.15
b.	Non - encumbered					
	- Number of shares	61650	45750	480650	61650	893850
	- Percentage of shares (as a % of the total shareholding of promotor and promotor group)	1.23	0.91	9.56	1.23	17.78
	- Percentage of shares (as a % of the total share capital of the company)	0.29	0.22	2.23	0.29	4.15

	PARTICULARS	3 Month ended
	Pending at the beginning of the quarter	-
	Received during the quarter	2
	Disposed of during the quarter	2
	Remaining unresolved at the end of the quarter	-

## Notes:

1. The above results were duly considered by the Audit Committee on 15<sup>th</sup> May, 2012, and taken on record by the Board of Directors of the Company along with Limited Review Report carried out by the Auditors at its meeting held on 15<sup>th</sup> May, 2012.
2. Limited Review financial results for the quarter ended 31/03/2012 have been consolidated with that of Lyka BDR International Ltd., as approved by their Board.
3. During the quarter Company has charged Rs. 24.73 lacs being depreciation on revalued assets.
4. The Company has capitalised a sum of Rs. 15.01 lacs being Interest towards the Term Loan for Tarapur Upgradation, during the quarter.
5. Exceptional items during the quarter includes :
  - i) In respect of subsidiary company Lyka BDR International Ltd., Profit of Rs. 412.20 lacs on sale of Intangible Assets.
  - ii) Profit of Rs. 759.39 lacs on sale of Fixed Assets.
6. The Company's factory at Tarapur is under upgradation. In view of this, the production has been suspended.
7. Accounting year of the Company has been extended by six months i.e. from 30<sup>th</sup> September, 2011 to 31<sup>st</sup> March, 2012 covering a period of 18 months which has been approved by the Registrar of Companies, Gujarat, vide their letter dated 30/09/2011.
8. The Company has one Single Segment "Pharmaceuticals".
9. In respect of subsidiary company Lyka BDR International Ltd., Fringe Benefit tax in arrears of Rs. 6.45 lacs plus interest as applicable for A.Y. 2009-10
10. Previous periods figures have been regrouped/rearranged wherever necessary.
11. Audit qualifications in respect of Audited Accounts for 2009-10 and management comments thereon are detailed below:

Regarding the Revaluation of its Fixed Assets again and writing off/adjustment of stocks, overdue debtors, loans & advances and deferred revenue expenditure, the management is of the view that such extra-ordinary items relating to the past years could legitimately be written off against the 'net present replacement value'

12. In the case of subsidiary company Lyka BDR International Ltd.,
  - 1) Note No. 2: mentions of the Contingent Liability which in the opinion of the management do not warrant any provisions because of the nature stated therein.
  - 2) Note No. 9: deal with Loans & Advances, Sundry Debtors & Sundry Creditors which are pending as on the date of the Balance sheet and are being addressed subsequently thereof.

For L YKA LABS LIMITED

  
(N. I. GANDHI)

Chairman & Managing Director